A shortage of commercially available Tamiflu® (oseltamivir phosphate) oral suspension is contributing to dosing errors in healthcare facilities. The Pennsylvania Patient Safety Authority has received two reports related to the concentration of Tamiflu. In each case, it was thought that the commercially available 12 mg/mL product and not a pharmacy-compounded 15 mg/mL suspension would be dispensed.